鹭燕医药(002788) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥3,427,477,655.39, representing a 31.83% increase compared to ¥2,599,969,607.65 in the same period last year[7]. - Net profit attributable to shareholders was ¥44,408,937.65, up 37.15% from ¥32,379,175.19 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥43,627,126.31, reflecting a 35.38% increase from ¥32,226,007.98 in the previous year[7]. - The basic earnings per share increased to ¥0.23, a rise of 35.29% compared to ¥0.17 in the same period last year[7]. - Operating revenue increased by 31.83% year-on-year, driven by sustained growth in Fujian province and rapid growth from newly acquired companies in Sichuan and Jiangxi[15]. - Net profit attributable to shareholders increased by 37.15% year-on-year, attributed to business growth[15]. - Cash received from sales of goods and services rose by 36.27% year-on-year, due to business growth[15]. - The company reported a total comprehensive income of CNY 44,218,057.67 for Q1 2019, up from CNY 35,084,703.72 in Q1 2018[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,664,044,490.65, up 9.78% from ¥6,070,516,641.66 at the end of the previous year[7]. - The net assets attributable to shareholders increased to ¥1,618,006,749.51, a 3.10% rise from ¥1,569,385,019.24 at the end of the previous year[7]. - Total current assets increased to CNY 5,556,521,656.92 as of March 31, 2019, up from CNY 4,982,328,336.45 at the end of 2018, representing a growth of approximately 11.5%[27]. - Total liabilities reached CNY 4,964,437,833.05, up from CNY 4,416,939,154.54, marking an increase of around 12.4%[28]. - Short-term borrowings increased significantly to CNY 2,759,595,846.76 from CNY 2,122,354,488.80, a rise of approximately 30.1%[27]. - The total liabilities increased to CNY 1,912,958,526.23 from CNY 1,675,569,675.49, marking a 14% rise[34]. Cash Flow - The net cash flow from operating activities was negative at -¥641,202,280.14, a decline of 19.05% compared to -¥538,596,759.64 in the same period last year[7]. - The cash flow from operating activities showed a net outflow of CNY 641.20 million, worsening from a net outflow of CNY 538.60 million in the previous year[46]. - The company reported cash inflows from financing activities of CNY 1.57 billion, up from CNY 1.07 billion in the previous year, marking a growth of 47.3%[46]. - The cash inflow from sales of goods and services was CNY 3.48 billion, compared to CNY 2.55 billion in the previous year, showing a growth of 36.3%[44]. - The company reported a decrease in employee compensation payable to CNY 12,109,999.03 from CNY 33,661,551.33, a reduction of approximately 64.0%[28]. Research and Development - Research and development expenses surged by 177.15% year-on-year, reflecting increased investment in R&D[15]. - Research and development expenses for Q1 2019 were CNY 818,182.33, compared to CNY 295,213.35 in the previous year, indicating a significant increase[35]. Shareholder Information - The company reported a total of 23,568 common shareholders at the end of the reporting period[11]. - The largest shareholder, Xiamen Maidi Ken Technology Co., Ltd., held 35.34% of the shares, amounting to 67,945,200 shares[11]. Other Observations - The company’s contract liabilities were not reported in the provided data, indicating a potential area for further investigation[33]. - The company’s cash flow management strategies and future product development plans were not detailed in the provided data, suggesting a need for further insights in future reports[33]. - The company has not undergone an audit for the first quarter report[58]. - The company adjusted available-for-sale financial assets of CNY 300,000 to other equity instruments[57].